|Videos|September 19, 2022

Dr. Shore on next steps with PARP inhibitors in prostate cancer

“There’s a tremendous amount of work going on right now with PARP inhibitors in the resistant stage, but now also we’re looking at them in the sensitive stage,” says Neal D. Shore, MD.

Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME